This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking I agree you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our Cookie Settings . Please view our Cookie Policy to learn more about the use of cookies on our website.
Manage your cookiesI agree
Cookie Settings
Cookie Settings
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookie
Share this article
Share this article
ATLANTA, Feb. 9, 2021 /PRNewswire/ Covanos, Inc., a privately-held medical technology company that is developing C-HEART, a PC-based software product that uses proprietary advances in computational fluid dynamics to rapidly and non-invasively diagnose the severity of coronary artery blockages, today announced that it has named Mark D. Carlson, MD, MA to the position of Senior Vice President and Chief Medical Officer. We are pleased to welcome Mark Carlson to the Covanos team, said Russell M. Medford, M.D., Ph.D., chairman and chief executive officer of Covanos. Mark s executive experience in developing and commercializing cardiac medical technology for some of the largest global businesses in the field positions Covanos well as we transition to a commercial enterprise later this year and pursue our mission to serve patients and reduce global healthcare costs.
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results
News provided by
Share this article
Share this article
RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA
® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021.
Published: Feb 01, 2021
AngioDynamics Appoints Richard C. Rosenzweig
Senior Vice President, General Counsel and Secretary,
Promotes Juan Carlos Serna to Senior Vice President,
Scientific & Clinical Affairs
LATHAM, N.Y. (BUSINESS WIRE) AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Richard C. Rosenzweig as Senior Vice President, General Counsel, effective January 31, 2021. Mr. Rosenzweig will also serve as Corporate Secretary to the AngioDynamics Board of Directors.
Mr. Rosenzweig succeeds Stephen Trowbridge who has served as Executive Vice President, Chief Financial Officer, and General Counsel since February 2020. Mr. Trowbridge will continue in his role as Executive Vice President and Chief Financial Officer.
Share this article
WOODCLIFF LAKE, N.J., Jan. 20, 2021 /PRNewswire/
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical Officer (CCLO) of its Oncology Business Group. In this role, Dr. Woodman will have full oversight and responsibility for the strategic and operational leadership of the company s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He will also serve as a member of the Oncology Executive Leadership team.
Dr. Richard Woodman
Dr. Woodman, who has 18 years of pharmaceutical experience in several different functional areas at both large and small biotech organizations, will lead the clinical team s development of Eisai s next generation oncology products by managing the design protocols and implementation of all oncology clinical trials. He w